Table 1 Baseline characteristics and univariate analysis
Baseline characteristic | Value (N = 1408) | ICU mortality | P-value | Hospital mortality | P-value | ||
|---|---|---|---|---|---|---|---|
Alive | Dead | Alive | Dead | ||||
Age (years), mean (SD) | 56.8 (16.1) | 57.3 | 56.3 | 0.1770 | 56.3 | 57.1 | 0.4132 |
Apache II Score, mean (SD) | 23.0 (7.91) | 21.3 | 24.9 | 0.0000 | 20.4 | 24.5 | 0.0000 |
Male gender, N (%) | 821 (58.3%) | 437 (60.7%) | 384 (55.8%) | 0.06336 | 317 (64.2%) | 504 (55.1%) | 0.00104 |
Type of malignancy | Â | Â | Â | 0.7762 | Â | Â | 0.63671 |
Hematology, N (%) | 453 (32.2%) | 229 (31.8%) | 224 (32.6%) | Â | 163 (33.0%) | 290 (31.8%) | Â |
 Lymphoma | 191 (13.6%) |  |  |  |  |  |  |
 Leukemia | 188 (13.4%) |  |  |  |  |  |  |
 Multiple Myeloma | 66 (4.6%) |  |  |  |  |  |  |
 Others | 8 (0.6%) |  |  |  |  |  |  |
Solid, N (%) | 955 (67.8%) | 491 (68.2%) | 464 67.4%) | Â | 331 (67.0%) | 624 (68.2%) | Â |
 Gastrointestinal Tumors | 248 (17.6%) |  |  |  |  |  |  |
 Breast Cancer | 143 (10.2%) | ||||||
 Lung Cancer | 138 (9.8%) | ||||||
 Gynecologic Tumors | 69 (4.9%) | ||||||
 Bladder Cancer | 60 (4.3%) | ||||||
 Prostate Cancer | 43 (3.0%) | ||||||
 Pancreatic Cancer | 34 (2.4%) | ||||||
 Renal Cell Carcinoma | 31 (2.2%) | ||||||
 Others | 176 (12.5%) | ||||||
 Unknown primary site | 13 (0.9%) | ||||||
SEER stage, N (%) |  |  |  | < 0.0001 |  |  | < 0.0001 |
 In Situ | 9 (0.6%) | 5 (0.7%) | 4 (0.6%) |  | 3 (0.6%) | 6 (0.7%) |  |
 Localized | 111 (7.9%) | 74 (10.3%) | 37 (5.3%) |  | 55 (11.1%) | 56 (6.1%) | |
 Regional | 275 (19.5%) | 170 (23.6%) | 105 (15.3%) |  | 124 (25.1%) | 151 (16.5%) | |
 Distant | 458 (32.5%) | 193 (26.8%) | 265 (38.5%) |  | 123 (25%) | 335 (36.7%) | |
 Unknown (Unstaged) | 38 (2.7%) | 16 (2.2%) | 22 (3.2%) |  | 6 (1.2%) | 32 (3.5%) | |
 Not applicable | 453 (32.2%) | 229 (31.8%) | 224 (32.6%) |  | 163 (33.0%) | 290 (31.7%) | |
 Not available | 64 (4.5%) | 33 (4.6%) | 31 (4.5%) |  | 20 (4%) | 44 (4.8%) | |
Recent Chemotherapy, N (%) | Â | Â | Â | 0.921 | Â | Â | 0.19771 |
 Yes | 402 (28.6%) | 206 (28.6%) | 196 (28.5%) |  | 151 (30.7%) | 251 (27.5%) |  |
 No | 999 (71%) | 509 (71.2%) | 490 (71.2%) |  | 339 (68.6%) | 660 (72.2%) | |
 No available data | 7 (0.4%) | 5 (0.2%) | 2 (0.3%) |  | 4 (0.7%) | 3 (0.3%) | |
Smoking, N (%) | Â | Â | Â | 0.37882 | Â | Â | 0.0191 |
 Yes | 631 (44.8%) | 330 (45.8%) | 301 (43.8%) |  | 242 (49%) | 389 (42.6%) |  |
 Not available | 117 (8.3%) | 61 (8.5%) | 56 (8.1%) |  | 40 (8.1%) | 77 (8.4%) | |
Neutropenia, N (%) | 272 (19.3%) | 142 (19.7%) | 130 (18.9%) | 0.69443 | 106 (21.5%) | 166 (18.2%) | 0.13496 |
Thrombocytopenia, N (%) | 556 (39.5%) | 244 (33.9%) | 312 (45.3%) | 0.00001 | 157 (31.8%) | 399 (43.7%) | 0.00001 |
Mechanical ventilation, N (%) | 591 (42%) | 230 (31.9%) | 361 (52.5%) | < 0.0001 | 138 (27.9%) | 453 (49.6%) | < 0.0001 |
Positive cultures, N (%) | 836 (59.4%) | 380 (52.8%) | 456 (66.3%) | < 0.0001 | 247 (50%) | 589 (64.4%) | < 0.0001 |
Acute kidney injury, N (%) | Â | Â | Â | 0.37852 | Â | Â | 0.38032 |
 Yes | 579 (41.1%) | 323 (44.9%) | 256 (37.2%) |  | 228 (46.1%) | 351 (38.4%) |  |
 No | 551 (39.1%) | 293 (40.1%) | 258 (37.5%) |  | 203 (41.1%) | 348 (38.1%) | |
 Not available | 278 (19.8%) | 104 (15%) | 174 (25.3%) |  | 63 (12.8%) | 215 (23.5%) | |
Elevated total bilirubin level mg/dl, N (%) | Â | Â | Â | 0.00009 | Â | Â | 0.00004 |
 Yes | 195 (13.8%) | 80 (11.1%) | 115 (16.7%) |  | 49 (9.9%) | 146 (16%) |  |
 No | 875 (62.2%) | 494 (68.6%) | 381 (55.4%) |  | 359 (72.7%) | 516 (56.5%) | |
 Not available | 338 (24%) | 146 (20.3%) | 192 (27.9%) |  | 86 (17.4%) | 252 (27.5%) | |
Elevated lactic acid level mmol/l, N (%) | Â | Â | Â | 0.00164 | Â | Â | 0.00017 |
 Yes | 918 (65.2%) | 437 (60.7%) | 481 (69.9%) |  | 284 (57.5%) | 634 (69.4%) |  |
 No | 370 (26.3%) | 212 (29.4%) | 158 (23%) |  | 155 (31.4%) | 215 (23.5%) | |
 Not available | 120 (8.5%) | 71 (9.9%) | 49 (7.1%) |  | 55 (11.1%) | 65 (7.1%) | |